Clinical Trials Browser

Intermediate Risk Non-Muscle Invasive Bladder Cancer

Carcinoma, Transitional Cell

Prostatic Neoplasms

Prostatic Neoplasms

Carcinoma, Renal Cell

Prostatic Neoplasms

Carcinoma, Carcinoma, Renal Cell

Non-Muscle Invasive Bladder Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Prostatic Neoplasms

Clear-cell metastatic renal cell carcinoma, Kidney Neoplasms

Prostatic Neoplasms, Castration-Resistant

Prostate Cancer Screening

Prostate Cancer Metastatic

Prostatic Neoplasms

Neoplasms, Prostatic Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

Prostatic Neoplasms, Recurrence

Metastatic Castration-Resistant Prostate Cancer

Carcinoma, Renal Cell

Prostatic Neoplasms

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Prostatic Neoplasms

Carcinoma, Transitional Cell

Prostatic Neoplasms

Oligometastatic Prostate Cancer (OMPC)

Prostatic Neoplasms

Urinary Bladder Neoplasms

Prostatic Neoplasms

Testicular Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Kidney Neoplasms, Ureteral Neoplasms, Vesico-Ureteral Reflux, Nephrolithiasis

Transitional Cell Cancer of Renal Pelvis and Ureter

Colonic Neoplasms, Lung Neoplasms, Prostatic Neoplasms

PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

Urinary Bladder Neoplasms

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Localized Prostate Cancer

Urinary Bladder Neoplasms

Carcinoma, Transitional Cell

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Agnosia, Carcinoma, Renal Cell

Carcinoma, Transitional Cell

Prostatic Neoplasms

Carcinoma, Renal Cell, Kidney Neoplasms

Clinical Trials

ABLE-32

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

AMPLIFY

Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

CLARIFY

LITESPARK-033

MoonRISe-1

MoonRISe-3

MK-2400-001

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

KLK2-PASenger

MUSIC-Screen

OMAHA-003

MK-5684-004

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

FORAGER-2

MEVPRO-1

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

STRIKE

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

GAIN-BCG

MEVPRO-3

A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

PSMA-DC

AcTFirst

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Solar-Stage

RPLND

OPTION-DDR

Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer

SMILe

UCM301

ID-COMET

A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

rechARge

ASPIRE

A Study of Surgical Techniques During Cystectomy

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

EvoPAR-PR01

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

R.E.C.K vs Exparel in Robotic Nephrectomy

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

ViPER

STROKER